Published • loading... • Updated
Base Editing Therapy Achieves Full Transfusion Independence in Genetic Blood Disorders
The therapy delivered rapid engraftment and sustained hemoglobin responses, with 100% of treated patients achieving transfusion independence or freedom from VOCs, researchers said.
- On Monday, Cell Stem Cell published clinical research from CorrectSequence Therapeutics demonstrating that CS-101 and CS-206 base-editing therapies achieved consistent safety and efficacy in hemoglobinopathy patients across diverse genetic backgrounds.
- Correctseq employs its proprietary transformer Base Editor , which uses a 'lock-and-key' design enabling precise gene editing without cutting DNA and minimizing off-target risks.
- A 21-year-old sickle cell patient achieved transfusion independence and freedom from VOCs for 15.5 months, while three TDT patients from Laos, Malaysia, and Pakistan attained sustained transfusion independence after 17.5 months of follow-up.
- TBE achieved superior engraftment compared to conventional Cas9 and Cas12a, with neutrophil recovery in 13 days and platelet recovery in 21 days versus 27 and 35 days respectively.
- Correctseq is accelerating multiple pipelines toward global IND submission, expanding its base-editing platform to treat metabolic and cardiovascular conditions including MASH and hypertriglyceridemia beyond hemoglobinopathies.
Insights by Ground AI
46 Articles
46 Articles
Daily Journal+44 Reposted by 44 other sources
Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia.
·Cherokee County, United States
Read Full Article
Base editing therapy achieves full transfusion independence in genetic blood disorders
SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- On September 7, 2026, Shanghai, Cell Stem Cell published online clinical research from CorrectSequence Therapeutics (Correctseq) in collaboration with multiple institutions in a paper titled "Clinical base editing for β-hemoglobinopathies across different genetic backgrounds", demonstrating that CS-101/CS-206—base-editing therapy developed with the transformer Base Editor (tBE)—achieved consistent efficacy…
Coverage Details
Total News Sources46
Leaning Left4Leaning Right4Center32Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
Factuality
To view factuality data please Upgrade to Premium
